The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2021 Euromoney, a part of the Euromoney Institutional Investor PLC.

Pharmaceutical producer Pliva reports 72% y/y EBIT drop in Jan-Sep.

Pharmaceutical producer Pliva reports 72% y/y EBIT drop in Jan-Sep. The largest pharmaceutical producer in the region, Pliva, announced that its EBIT slumped by 72.3% y/y to USD 62.3mn on revenue decline of 12.2% to USD 797mn. The decline was expected given the exit of the company from the proprietary market and focusing on generics production launched last year. This reduced the revenues as the company no more received revenues from royalties on proprietary drugs. The sales of the company, however, increased by 3.8% y/y to USD 762.6mn, as generics drugs sale soared by 15.7% to USD 667.3mn. The largest growth was registered on the US market - of 42.7% y/y to USD 198.3mn, in Spain – of 22.6% to USD 20.7mn, in UK – of 26.2% to USD 23.4mn, in Russia - of 18.7% y/y to USD 56.5mn, and in Poland - of 16.4% to USD 73.9mn. A drop in generics sales was registered only in Croatia , by 6% y/y to USD 94.8mn, and in Italy , by 54.9% to USD 7.6mn. In addition, the planned changes to be discussed at the forthcoming general meeting of the company were said to include the possibility for capital increase to not more than HRK 929.6mn

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree